These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Search MEDLINE/PubMed

  • Title: [Neoadjuvant chemotherapy in muscle-invasive bladder cancer].
    Author: Miyanaga N, Akaza H.
    Journal: Gan To Kagaku Ryoho; 2007 Nov; 34(11):1745-9. PubMed ID: 18030008.
    Abstract:
    Radical cystectomy is the standard treatment for patients with muscle-invasive bladder cancer. Bladder cancer is a chemoresponsive disease and should be dealt with in a multimodality approach. Neoadjuvant chemotherapy is intended for patients with operable clinical stage T2 to T4a muscle-invasive disease to improve survival. Meta-analysis of cisplatin-containing combination neoadjuvant chemotherapy trials revealed a 5% difference in favor of neoadjuvant chemotherapy. Bladder preservation in selected patients on the basis of response to neoadjuvant chemotherapy is a feasible approach. The goal now must be to find more effective drugs and to better predict the individual response to therapy.
    [Abstract] [Full Text] [Related] [New Search]